Streetbeat News

Products Services

PSTX

Poseida Therapeutics shares rose after receiving FDA's Regenerative Medicine Advanced Therapy designation for P-BCMA-ALLO1, a treatment for relapsed/refractory multiple myeloma.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:05 pm

PSTX

Poseida Therapeutics has received the Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its P-BCMA-ALLO1 treatment targeting relapsed/refractory multiple myeloma. This designation could expedite the development and review process, potentially bringing the therapy to market faster.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:04 pm

ICCM

IceCure Medical's ProSense cryoablation technology has been highlighted in a study published in The British Journal of Radiology, demonstrating a 97.7% technical success rate in treating tumors of the lung, bone, and soft tissues. The study, conducted at the European Institute of Oncology, found ProSense to be safer, more cost-effective, and easier to manage compared to argon-based systems.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:03 pm

GCI

MGM

Gannett Co., Inc. (NYSE:GCI) has announced a multi-year partnership with BetMGM, making BetMGM the preferred online sportsbook and casino partner for USA TODAY Sports. This partnership will provide sports betting odds and information across the USA TODAY Network.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:02 pm

ACN

FG

F&G Annuities & Life, Inc (NYSE:FG) has partnered with Accenture (NYSE:ACN) to enhance its technology platform using Accenture's Life Insurance and Annuity Platform. This collaboration aims to optimize and scale F&G's operations for future growth.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:00 pm

TBPH

Theravance Biopharma (NASDAQ:TBPH) has received mixed analyst ratings over the past three months, with a recent average price target of $12.25, down from $15.00. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance. Theravance Biopharma is a biopharmaceutical company focused on organ-selective medicines, with a recent revenue growth rate of 3.69% and a net margin of -115.94%.

Portfolio Pulse from Benzinga Insights

September 16, 2024 | 12:00 pm

EVAX

Evaxion Biotech shares rise as the company announces positive one-year data from its phase 2 trial of EVX-01, an AI-designed personalized cancer vaccine.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:58 am

NCNA

NuCana's shares rose following the announcement of positive final data from their Phase 2 NuTide:701 study, presented at the ESMO Congress. The study involved NUC-7738 combined with pembrolizumab for treating metastatic melanoma in patients who were refractory to or had relapsed on prior PD-1 inhibitor therapy.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:55 am

ADAG

Adagene shares rose following the announcement of new clinical data from its Phase 1b/2 trial of ADG126 in combination with Keytruda, presented at the ESMO Congress.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:53 am

IOBT

IO Biotech shares rise following positive Phase 2 trial results of their cancer vaccine candidate IO102-IO103, in combination with Merck's KEYTRUDA, presented at the 2024 ESMO Congress.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:52 am